

Register of Certificates of Supplementary Protection and Applications

Certificates of Supplementary Protection and Applications - Human Use

Certificate of Supplementary Protection (CSP) and/or Application Number	Medicinal Ingredient(s)	New Drug Submission (NDS) Number	Patent Number	Patent Expiry Date yyyy-mm-dd	Application Status	CSP Term Begins yyyy-mm-dd	CSP Term Ends yyyy-mm-dd
900039	abemaciclib	215268	2747055	2029-12-15	Issued	2029-12-16	2031-12-15
900096	abrocitinib	245854	2900703	2034-02-11	Issued	2034-02-12	2036-02-11
900045	acalabrutinib	214504	2841886	2032-07-11	Issued	2032-07-12	2034-07-11
900056	alpelisib	226941	2734819	2029-09-08	Issued	2029-09-09	2031-09-08
900114	amivantamab	254440	2893505	2033-11-21	Issued	2033-11-22	2035-11-21
900089	anifrolumab	246187	2713981	2029-02-06	Withdrawn		
900035	antihemophilic factor (recombinant, B-domain deleted, pegylated) (also known as damoctocog alfa pegol)	210935	2586379	2025-11-14	Issued	2025-11-15	2027-11-14
900027	apalutamide	211942	2875767	2033-06-04	Issued	2033-06-05	2033-07-04
900100	asciminib hydrochloride	255700	2868958	2033-05-09	Issued	2033-05-10	2035-05-09
900113	atogepant	253186	2817100	2031-11-10	Issued	2031-11-11	2033-11-10
900095	avacopan	248255	2747522	2029-12-21	Issued	2029-12-22	2031-12-21
900127	avatrombopag maleate	251688	2660283	2027-08-08	Issued	2027-08-09	2029-08-08
900088	avelumab	204052	2856895	2032-11-21	Issued	2032-11-22	2032-12-19
900026	baricitinib	193687	2718271	2029-03-10	Issued	2029-03-11	2031-03-10
900102	belumosudil mesylate	245791	2926478	2033-10-07	Issued	2033-10-08	2035-10-07
900103	belzutifan	254495	2919397	2034-09-05	Issued	2034-09-06	2036-09-05
900012	benralizumab	204008	2685222	2028-05-14	Issued	2028-05-15	2030-05-14
900093	bimekizumab	238499	2823812	2032-01-11	Issued	2032-01-12	2034-01-11
900028	bictegravir sodium / emtricitabine / tenofovir alafenamide hemifumarate	203718	2416757	2021-07-20	Refused		
900020	brigatinib	210369	2723961	2029-05-21	Issued	2029-05-22	2031-05-21

Certificate of Supplementary Protection (CSP) and/or Application Number	Medicinal Ingredient(s)	New Drug Submission (NDS) Number	Patent Number	Patent Expiry Date yyyy-mm-dd	Application Status	CSP Term Begins yyyy-mm-dd	CSP Term Ends yyyy-mm-dd
900015	brodalumab	195317	2663537	2027-10-01	Issued	2027-10-02	2029-10-01
900060	brolocizumab	226224	2727839	2029-06-25	Issued	2029-06-26	2031-06-25
900057	cabotegravir (cabotegravir sodium)	227315	2606282	2026-04-28	Issued	2026-04-29	2028-04-28
900097	cabotegravir / rilpivirine	227315	3060290	2031-01-24	Issued	2031-01-25	2033-01-24
900126	capivasertib	274859	2701057	2028-10-09	Issued	2028-10-10	2030-10-09
900063	cedazuridine / decitabine	234610	2702274	2028-10-16	Issued	2028-10-17	2030-10-16
900022	cenegermin	218145	2346257	2019-10-11	Refused		
900118	ciltacabtagene autoleucel	262122	3019453	2037-08-10	Issued	2037-08-11	2038-02-10
900011	coagulation factor IX (recombinant), pegylated	201114	2462930	2022-10-09	Refused		
900052	coagulation factor IX (recombinant), pegylated	201114	2665480	2027-10-04	Refused		
900115	concizumab	267120	2745317	2029-12-18	Issued	2029-12-19	2031-12-18
900084	COVID-19 vaccine (ChAdOx1-S [recombinant])	252495	2837274	2032-05-25	Refused		
900019	crisaborole	206906	2597982	2026-02-16	Issued	2026-02-17	2028-02-16
900041	dacomitinib	214572	2565812	2025-04-25	Issued	2025-04-26	2027-04-25
900135	danicopan	274338	2940772	2035-02-25	Issued	2035-02-26	2037-02-25
900119	daridorexant hydrochloride	255507	2873341	2033-06-03	Issued	2033-06-04	2035-06-03
900058	darolutamide	226146	2777896	2030-10-27	Issued	2030-10-28	2032-10-27
900017	darunavir ethanolate / cobicistat / emtricitabine / tenofovir alafenamide hemifumarate	199705	2678907	2028-02-22	Issued	2028-02-23	2030-02-22
900110	deucravacitinib	259397	2890981	2033-11-07	Issued	2033-11-08	2035-11-07
900106	difelikefalin (difelikefalin acetate)	254548	2667155	2027-11-12	Issued	2027-11-13	2029-11-12
900051	dolutegravir (dolutegravir sodium) / lamivudine	220275	3003988	2031-01-24	Issued	2031-01-25	2033-01-24

Certificate of Supplementary Protection (CSP) and/or Application Number	Medicinal Ingredient(s)	New Drug Submission (NDS) Number	Patent Number	Patent Expiry Date yyyy-mm-dd	Application Status	CSP Term Begins yyyy-mm-dd	CSP Term Ends yyyy-mm-dd
900021	dolutegravir (dolutegravir sodium) / rilpivirine (rilpivirine hydrochloride)	206402	2606282	2026-04-28	Refused		
900034	doravirine	211293	2794377	2031-03-28	Issued	2031-03-29	2033-03-28
900004	dupilumab	201285	2737044	2029-10-27	Issued	2029-10-28	2031-10-27
900010	durvalumab	202953	2778714	2030-11-24	Issued	2030-11-25	2032-11-04
900128	elranatamab	273519	2925329	2036-03-30	Issued	2036-03-31	2038-03-30
900024	emicizumab	212635	2817964	2031-11-17	Issued	2031-11-18	2033-08-03
900053	entrectinib	227517	2693901	2028-07-08	Issued	2028-07-09	2030-07-08
900074	eptinezumab	233288	2836649	2032-05-21	Issued	2032-05-22	2034-05-21
900070	erdafitinib	224529	2796204	2031-04-28	Issued	2031-04-29	2033-04-28
900025	erenumab	208607	2746858	2029-12-18	Issued	2029-12-19	2031-12-18
900018	ertugliflozin	204724	2733795	2029-08-17	Issued	2029-08-18	2031-08-17
900076	estetrol monohydrate / drospirenone	236197	2448278	2022-05-23	Issued	2022-05-24	2024-05-23
900130	etrasimod (etrasimod L-arginine)	271038	3002540	2036-01-06	Issued	2036-01-07	2038-01-06
900099	faricimab	253904	2874554	2033-07-11	Issued	2033-07-12	2035-07-11
900129	finerenone	258231	3146285	2035-07-29	Issued	2035-07-30	2037-07-29
900033	fluticasone furoate, umeclidinium (as bromide), vilanterol (as trifenate)	204880	2781487	2030-11-29	Issued	2030-11-30	2032-11-29
900137	fruquintinib	275803	2958666	2035-09-07	Issued	2035-09-08	2037-09-07
900044	galcanezumab	219521	2802102	2031-06-07	Issued	2031-06-08	2033-06-07
900055	gilteritinib fumarate	227918	2760061	2030-05-06	Issued	2030-05-07	2032-05-06
900131	givosiran (givosiran sodium)	237194	2925357	2034-10-03	Issued	2034-10-04	2035-10-10
900062	glasdegib	225793	2690953	2028-06-16	Issued	2028-06-17	2030-06-16
900001	glecaprevir / pibrentasvir	202233	2807847	2031-10-12	Refused		

Certificate of Supplementary Protection (CSP) and/or Application Number	Medicinal Ingredient(s)	New Drug Submission (NDS) Number	Patent Number	Patent Expiry Date yyyy-mm-dd	Application Status	CSP Term Begins yyyy-mm-dd	CSP Term Ends yyyy-mm-dd
900133	glofitamab	265517	2951599	2035-08-03	Issued	2035-08-04	2037-08-03
900014	glycopyrronium (as bromide) / formoterol fumarate dihydrate	201306	2763936	2030-05-28	Refused		
900003	guselkumab	200590	2635692	2026-12-28	Issued	2026-12-29	2028-12-28
900085	inclisiran sodium	243470	2892160	2033-12-05	Issued	2033-12-06	2035-12-05
900090	Infigratinib phosphate	246904	2781431	2030-12-06	Refused		
900032	inotersen (inotersen sodium)	214274	2797792	2031-04-29	Issued	2031-04-30	2033-04-29
900023	insulin glargine / lixisenatide	207006	2740685	2029-10-09	Issued	2029-10-10	2031-10-09
900029	lanadelumab	213920	2786019	2031-01-06	Issued	2031-01-07	2033-01-06
900043	larotrectinib (larotrectinib sulfate)	219998	2741313	2029-10-21	Issued	2029-10-22	2031-10-21
900066	lefamulin (supplied as lefamulin acetate)	233292	2678795	2028-03-19	Issued	2028-03-20	2030-03-19
900069	lemborexant	231286	2811895	2031-09-20	Issued	2031-09-21	2033-09-20
900109	lenacapavir (lenacapavir sodium)	262999	3021227	2037-08-17	Issued	2037-08-18	2037-11-03
900007	letermovir	204165	2524069	2024-04-17	Issued	2024-04-18	2026-04-17
900009	lifitegrast	199810	2609053	2026-05-17	Issued	2026-05-18	2028-05-17
900040	lorlatinib	215733	2863892	2033-02-20	Issued	2033-02-21	2034-02-23
900087	lurbinectedin	247485	2455768	2022-08-06	Issued	2022-08-07	2024-08-06
900071	luspatercept	236441	2733911	2029-08-13	Issued	2029-08-14	2031-08-13
900104	lutetium (¹⁷⁷ Lu) vipivotide tetraxetan	260951	2924360	2034-10-17	Issued	2034-10-18	2036-10-17
900086	macitentan / tadalafil	245848	2659770	2027-08-28	Issued	2027-08-29	2029-08-28
900111	mavacamten	258772	2915967	2034-06-19	Issued	2034-06-20	2036-06-19
900120	mirikizumab	266471	2901462	2034-03-04	Issued	2034-03-05	2036-03-04

Certificate of Supplementary Protection (CSP) and/or Application Number	Medicinal Ingredient(s)	New Drug Submission (NDS) Number	Patent Number	Patent Expiry Date yyyy-mm-dd	Application Status	CSP Term Begins yyyy-mm-dd	CSP Term Ends yyyy-mm-dd
900002	neisseria meningitidis grp B recombinant lipoprotein 2086 subfamily A / neisseria meningitidis grp B recombinant lipoprotein 2086 subfamily B	195550	2463476	2022-10-11	Issued	2022-10-12	2024-10-11
900122	nivolumab / relatlimab	256629	2877746	2033-07-02	Issued	2033-07-03	2035-07-02
900008	olaratumab	203478	2680945	2026-06-19	Issued	2026-06-20	2028-06-19
900072	ozanimod (ozanimod hydrochloride)	232761	2723904	2029-05-14	Issued	2029-05-15	2031-05-14
900073	ozanimod (ozanimod hydrochloride)	232761	2780772	2030-11-15	Withdrawn		
900091	palovarotene	252065	2809374	2031-08-31	Issued	2031-09-01	2033-08-31
900094	pemigatinib	242569	2876689	2033-06-12	Issued	2033-06-13	2035-06-12
900139	perfluorohexyloctane	272066	2997744	2033-09-12	Pending		
900140	perfluorohexyloctane	272066	2883003	2033-09-12	Pending		
900080	pertuzumab, trastuzumab	237402	2788253	2032-08-29	Refused		
900098	pneumococcal polysaccharide serotypes (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F)* *conjugated to diphtheria CRM197 protein	253111	2881420	2033-08-12	Withdrawn		
900092	pneumococcal polysaccharide serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F)* *conjugated to CRM197 protein	247042	2788680	2031-02-03	Issued	2031-02-04	2033-02-03

Certificate of Supplementary Protection (CSP) and/or Application Number	Medicinal Ingredient(s)	New Drug Submission (NDS) Number	Patent Number	Patent Expiry Date yyyy-mm-dd	Application Status	CSP Term Begins yyyy-mm-dd	CSP Term Ends yyyy-mm-dd
900121	pneumococcal polysaccharide serotypes(1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F)* *conjugated to diphtheria CRM197 protein	253111	3170344	2035-01-15	Issued	2035-01-16	2037-01-15
900067	polatuzumab vedotin	232303	2693255	2028-07-15	Issued	2028-07-16	2030-07-15
900079	ponesimod	239537	2968180	2035-12-10	Issued	2035-12-11	2036-04-29
900050	prasterone	198822	2696127	2028-08-08	Withdrawn		
900068	remdesivir	240551	2804840	2031-07-22	Issued	2031-07-23	2033-07-22
900016	ribociclib (ribociclib succinate)	203884	2734802	2029-08-20	Issued	2029-08-21	2031-08-20
900065	ripretinib	234688	2875970	2032-06-07	Issued	2032-06-08	2034-06-07
900042	risankizumab	215753	2816950	2031-11-02	Issued	2031-11-03	2033-11-02
900078	risdiplam	242373	2948561	2035-05-11	Issued	2035-05-12	2036-04-15
900124	ritlecitinib (ritlecitinib tosylate)	268723	2932425	2034-11-20	Issued	2034-11-21	2036-11-20
900031	rivaroxaban	211611	2451258	2022-06-07	Refused		
900046	romosozumab	197713	2607197	2026-04-28	Issued	2026-04-29	2028-04-28
900125	RSV subgroup A stabilized prefusion F protein / RSV subgroup B stabilized prefusion F protein	272785	2952131	2036-12-19	Issued	2036-12-20	2038-12-19
900061	satralizumab	233642	2699834	2029-09-25	Issued	2029-09-26	2031-09-25
900005	semaglutide	202059	2601784	2026-03-20	Issued	2026-03-21	2028-03-20
900054	siponimod	223225	2747437	2029-12-16	Withdrawn		
900059	siponimod	223225	2747992	2029-12-21	Issued	2029-12-22	2031-12-21
900117	somatogon	246729	2928269	2034-10-21	Issued	2034-10-22	2036-10-21
900134	sotatercept	283307	3030859	2037-07-14	Issued	2037-07-15	2039-07-14
900112	spesolimab	267362	2852994	2032-11-14	Issued	2032-11-15	2034-11-14
900038	suvorexant	160233	2670892	2027-11-30	Refused		

Certificate of Supplementary Protection (CSP) and/or Application Number	Medicinal Ingredient(s)	New Drug Submission (NDS) Number	Patent Number	Patent Expiry Date yyyy-mm-dd	Application Status	CSP Term Begins yyyy-mm-dd	CSP Term Ends yyyy-mm-dd
900107	tafasitamab	247025	2841738	2032-08-14	Issued	2032-08-15	2034-08-14
900048	talazoparib (talazoparib tosylate)	220584	2732797	2029-07-27	Issued	2029-07-28	2031-07-27
900136	tarlatamab	281963	2986848	2036-08-01	Issued	2036-08-02	2038-08-01
900101	tebentafusp	258717	2766505	2030-07-01	Issued	2030-07-02	2032-07-01
900082	tepotinib hydrochloride	242300	2693600	2028-04-29	Issued	2028-04-30	2030-04-29
900036	tezacaftor / ivacaftor	211292	2742821	2028-11-12	Issued	2028-11-13	2030-11-12
900105	tezepelumab	256188	2698382	2028-09-09	Issued	2028-09-10	2030-09-09
900108	tirzepatide	259103	2973352	2036-01-05	Issued	2036-01-06	2037-11-25
900030	tisagenlecleucel	213547	2820681	2031-12-09	Issued	2031-12-10	2033-12-09
900081	trastuzumab deruxtecan	242104	2928794	2035-01-28	Issued	2035-01-29	2036-04-16
900064	tucatinib	235295	2632194	2026-11-15	Issued	2026-11-16	2028-11-15
900049	upadacitinib	223734	2781891	2030-12-01	Issued	2030-12-02	2032-12-01
900006	varicella-zoster virus glycoprotein E (gE)	200244	2600905	2026-03-01	Refused		
900116	vericiguat	240862	2800697	2031-05-24	Issued	2031-05-25	2033-05-24
900138	vorasidenib	282910	2917358	2034-07-10	Issued	2034-07-11	2036-07-10
900075	zanubrutinib	242748	2902686	2034-04-22	Issued	2034-04-23	2036-03-02
900132	zilucoplan sodium	276757	2949985	2035-06-12	Issued	2035-06-13	2037-06-12

Certificates of Supplementary Protection and Applications - Veterinary Use

Certificate of Supplementary Protection (CSP) and/or Application Number	Medicinal Ingredient(s)	New Drug Submission (NDS) Number	Patent Number	Patent Expiry Date yyyy-mm-dd	Application Status	CSP Term Begins yyyy-mm-dd	CSP Term Ends yyyy-mm-dd
900083	ciclesonide	200882	2888428	2033-12-18	Issued	2033-12-19	2035-05-01
900077	esafoxolaner / eprinomectin / praziquantel	234676	2848317	2032-09-12	Refused		

Certificate of Supplementary Protection (CSP) and/or Application Number	Medicinal Ingredient(s)	New Drug Submission (NDS) Number	Patent Number	Patent Expiry Date yyyy-mm-dd	Application Status	CSP Term Begins yyyy-mm-dd	CSP Term Ends yyyy-mm-dd
900013	lotilaner	193712	2747354	2029-12-17	Issued	2029-12-18	2031-12-17
900047	sarolaner / moxidectin / pyrantel (as pyrantel pamoate)	210868	2882200	2033-09-04	Issued	2033-09-05	2034-09-27
900037	sarolaner / selamectin	190913	2828397	2032-02-23	Issued	2032-02-24	2033-11-07
900123	velagliflozin L-proline monohydrate	265785	2930034	2034-12-15	Issued	2034-12-16	2036-12-15